J.W. Cole Advisors Inc. Decreases Stake in Pfizer Inc. $PFE

J.W. Cole Advisors Inc. cut its position in shares of Pfizer Inc. (NYSE:PFE) by 8.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 235,077 shares of the biopharmaceutical company’s stock after selling 20,552 shares during the period. J.W. Cole Advisors Inc.’s holdings in Pfizer were worth $5,990,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Curio Wealth LLC raised its position in Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 1,098 shares during the period. Grey Fox Wealth Advisors LLC bought a new position in shares of Pfizer during the 3rd quarter valued at approximately $29,000. Harbor Asset Planning Inc. purchased a new stake in Pfizer during the 2nd quarter valued at $29,000. Howard Hughes Medical Institute bought a new stake in Pfizer in the second quarter worth $30,000. Finally, True Wealth Design LLC boosted its stake in Pfizer by 302.5% during the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 974 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of PFE stock opened at $26.83 on Thursday. The company has a market capitalization of $152.55 billion, a P/E ratio of 19.73 and a beta of 0.47. The company’s 50-day simple moving average is $25.57 and its two-hundred day simple moving average is $25.07. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.69. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The firm had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. During the same quarter in the previous year, the business earned $0.63 earnings per share. Pfizer’s quarterly revenue was down 1.2% on a year-over-year basis. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.4%. Pfizer’s dividend payout ratio is presently 126.47%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q4 beat — Pfizer reported stronger‑than‑expected Q4 revenue and adjusted EPS, which underpinned the rally and reassures investors that legacy drugs (like Eliquis) are offsetting COVID declines. Reuters: Pfizer beats fourth-quarter profit estimates
• Positive Sentiment: GLP‑1 mid‑stage success — topline VESPER‑3 data for MET‑097i (monthly injectable) showed up to ~12.3% placebo‑adjusted weight loss and maintained weight loss after switching from weekly to monthly dosing, giving Pfizer a credible entrant in the high‑growth obesity market. Reuters: Pfizer’s experimental drug shows up to 12.3% weight loss
• Positive Sentiment: Longer‑term catalysts — analysts and commentators highlight Pfizer’s expanded oncology portfolio (including Seagen assets) and AI partnerships as multi‑year growth drivers that could meaningfully re‑rate the stock if late‑stage trials succeed. MarketBeat: Pfizer earnings & pipeline analysis
• Neutral Sentiment: Analyst stance is cautious — major firms (Goldman, Citi and others) are largely Neutral/Hold with price targets near the current level, reflecting upside from the pipeline but offset by near‑term headwinds. InsiderMonkey: Goldman Sachs maintains Neutral on Pfizer TipRanks: Citi Hold commentary
• Negative Sentiment: Guidance and margin pressure — Pfizer reiterated FY‑2026 guidance that implies EPS of ~$2.80–3.00 (around or slightly below consensus) and flagged near‑term profit declines, which keeps investors cautious on 2026 growth and margins. BusinessWire: Pfizer reaffirms 2026 guidance
• Negative Sentiment: Structural revenue headwinds — declining COVID product sales, patent‑cliff impacts and an expected ~$1.5B hit in coming periods were cited by analysts as reasons the stock can lag despite beats. FT: vaccines and patent pressures weigh on sales
• Negative Sentiment: Mixed investor reaction to obesity data — some coverage flagged safety/signal questions and that Pfizer’s monthly dosing may still face tough competition from established GLP‑1 leaders (Lilly, Novo); that uncertainty contributed to earlier share weakness. MSN: mixed response to weight‑loss data
• Negative Sentiment: Program shifts — Pfizer and partners have paused certain modRNA shingles ambitions, showing the company is re‑prioritizing pipeline choices; such changes can be seen as conservative but remove near‑term optionality. TipRanks: Pfizer/BioNTech pause modRNA shingles ambitions

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on PFE shares. Scotiabank initiated coverage on shares of Pfizer in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 target price on the stock. HSBC reiterated a “buy” rating and set a $29.00 price target on shares of Pfizer in a report on Wednesday, December 10th. Morgan Stanley decreased their price objective on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research note on Friday, December 12th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Wednesday, December 17th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and issued a $26.00 price target on shares of Pfizer in a report on Wednesday, November 5th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $28.06.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.